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（１）抗体医薬はヒトが本来持つ免疫機能の一つである抗体の性質を利用した分子標的薬
であり、抗体医薬作製技術の革新的進歩によりバイオ医薬品に占める割合は急激に増加し
ている。しかしながら、現在、抗体医薬の創薬標的となるたん白質は期待されたほど多く
はなく、製薬企業間の新薬開発競争が激化しているため、候補抗体について競合グループ
に先駆けて臨床試験を開始し、またマーケットに導入する速度が求められる。このため、
抗体医薬品の製造方法開発期間を短縮化し、臨床試験を迅速に開始することによって候補
抗体の価値を開発早期に判断することの意義は大きい。一方、抗体医薬によく利用される
IgG 抗体について、共通のサブクラス間では抗体構造全体の 2/3 を占める定常領域の構造は
ほぼ共通と考えられる。更には可変領域の骨格構造も高い相同性があることが知られてい
る。このことから、組換え抗体医薬品の製造方法に一般的に用いられているカラムクロマ
トグラフィーにおいて、目的抗体の溶出挙動は、抗体タンパク質の一次構造から予測でき
ることが期待される。この予測方法の確立は製造方法開発期間の迅速化に繋がると考えら
れる。本研究では、モノクローナル抗体の精製に広く利用されているハイドロキシアパタ
イト充てん剤に関する溶出位置予測方法の確立を目的として、抗体構造と溶出挙動の相関
について、組換えモノクローナル抗体を用いての解明を試みた。 
 
（２）ハイドロキシアパタイトはインプラント材料としての臨床応用以外にも、中性付近
においてクロマトグラフィーが可能であり、かつ比較的高い特異性を有する精製用充てん
剤としての利用価値がある。その分離原理には陽イオン交換作用を持つリン酸基とタンパ
ク質表面上のカルボキシル基とのキレート結合能（金属アフィニティ結合能）を有するカ
ルシウム基が関与し、これらの複雑な相互作用により、タンパク質の微妙な構造の違いを
認識できると考えられている。カラムクロマトグラフィーにおける有効な溶出条件として、
リン酸ナトリウム濃度勾配溶出及び塩化ナトリウム濃度勾配溶出条件が知られており、リ
ン酸ナトリウム濃度勾配溶出モードにおいては、タンパク質の等電点と溶出位置に正の相
 関の傾向があることが知られている。 
 
（３）リン酸ナトリウム濃度勾配溶出条件における組換えモノクローナルヒト抗体の抗体
構造と溶出挙動との相関について検討した結果、(i) 可変領域と定常領域の両方が溶出挙動
に影響を与えている、(ii) 重鎖可変領域の塩基性アミノ酸の数と溶出位置に正の相関があり、
抗体等電点とは相関がない、(iii) この正の相関は塩基性アミノ酸のタンパク質表面の露出
度を考慮すると更に向上される（相関係数=0.87）、ことを見出した。 
 
（４）塩化ナトリウム濃度勾配溶出条件における組換えモノクローナルヒト抗体の抗体構
造と溶出挙動との相関について検討した結果、(i) 可変領域の寄与は小さく、定常領域が溶
出挙動に影響を与えており、サブクラスのみからの溶出位置の分類が可能である、(ii) 溶出
挙動に影響を与える相互作用機構として、金属アフィニティ結合と陽イオン交換作用が協
調的に作用していることが推察される、ことを見出した。 
 
（５）以上の結果、本研究により、組換えヒトモノクローナル抗体を用いたハイドロキシ
アパタイトクロマトグラフィーの溶出挙動はリン酸ナトリウム濃度勾配溶出条件、塩化ナ
トリウム濃度勾配溶出条件では異なり、溶出位置は抗体サブクラス、可変領域の一次構造
から予測可能であることが示唆された。これらの結果を応用することにより、抗体医薬製
造におけるハイドロキシアパタイトクロマトグラフィーの溶出条件の最適化について、一
次構造情報のみから迅速に予測することが可能であり、効率的な抗体精製方法の開発に役
立つことが考えられる。 
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ABBREVIATIONS 
 
MAb, monoclonal antibody 
rhMAb, recombinant human monoclonal antibody 
POC, proof of concept 
VH region, heavy chain variable region 
VL region, light chain variable region 
CH, heavy chain constant region 
CL, light chain constant region 
Fab, fragment, antigen binding 
Fc, fragment, crystallizable 
CDR, complementarity determining region 
PDB, Protein Data Bank 
pI, isoelectric point 
P-site, phosphate-site 
C-site, calcium-site 
NaPi, sodium phosphate 
NaCl, sodium chloride 
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tr, retention time 
I.D., inside diameter 
r
2, correlation coefficient 
SD, standard deviation 
CV, coefficient of variation 
Arg, arginine 
Lys, lysine 
Glu, glutamate 
Asp, aspartate 
His, histidine 
cDNA, complementary DNA 
RT-PCR, reverse transcriptase polymerase chain reaction 
IEF, isoelectric focusing analysis 
RSA, relative side chain solvent accessibility 
N-glycan, asparagine (N)-linked oligosaccharides 
CNa, peak sodium ion concentration by sodium phosphate gradient elution 
Cphos, peak phosphate ion concentration by sodium phosphate gradient elution 
CNaCl, peak sodium chloride concentration by sodium chloride gradient elution 
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GENERAL INTRODUCTION 
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1. Monoclonal Antibody Therapeutics 
Monoclonal antibody therapy (MAb therapy) is one of the molecularly-targeted 
therapies taking advantage of the properties of antibodies to bind specifically to the 
targets on the surface or exterior of host cells or invading pathogens [1–5]. The clinical 
trial of MAb therapy started [broke out?] with the advent of hybridoma technology 
developed by Köhler and Milstein in 1975 [6]. This technological innovation enabled us 
to produce a single, homogeneous murine antibody of predefined antigen specificity, 
and various therapeutic murine MAbs entered clinical trial in the early 1980s. In the 
next decade, the development of chimeric and humanized MAb technology (Fig. 1) 
reduced potential risks of immunogenicity and rapid clearance of murine antibodies in 
human therapy (Table 1) due to patients’ production of human anti-mouse antibodies [7, 
8]. Chimeric MAbs are composed of murine variable regions fused to human constant 
regions, and 67% of the total amino acid sequences are of human origin. Amino acid 
sequences of murine origin are further reduced in humanized MAbs by grafting murine 
hypervariable amino acid domains into human antibodies (approximately 90% human 
origin). Furthermore, advancements in genetic engineering techniques have finally 
provided fully recombinant human MAbs (rhMAbs) taking advantage of 
trans-chromosome and phage display technologies [9–11].  
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Fig. 1. Antibody engineering for humanization. Mouse- and human-derived amino acid 
sequences are drawn in pink and in blue, respectively. The percentages described below each 
antibody type show the occupancy fraction of human derived amino acid sequence. Chimeric 
antibody combines the mouse variable regions with the human constant regions. Humanized 
antibody is produced by CDR-grafting technology, and the variable regions consist of antigen 
binding CDRs of mouse origin in association with human framework regions. 
 
 
 
 
 
 
 
Table 1. 
Incidence of antibodies in humans administered monoclonal antibody drugs 
Antibody drug Antibody type Incidence 
Oncoscint (anti-TAG) mouse IgG1 55% 
OKT3 (anti-CD3) mouse IgG2a ~80% 
Rituxan (anti-CD20) chimeric IgG1 < 1% 
Simulect (anti-IL2Ra) chimeric IgG1 < 2% 
ReoPro (anti-GPIIb/IIIa) chimeric IgG1 Fab 7-19% 
Remicade (anti-TNF) chimeric IgG1 10-57% 
Erbitux (anti-EGFR) chimeric IgG1 5% 
Synagis (anti-RSV) humanized IgG1 < 1% 
Herceptin (anti-HER2) humanized IgG1 0.1% 
Zenapax (anti-IL2Ra) humanized IgG1 8% 
Campath (anti-CD52) humanized IgG1 < 2% 
Avastin (anti-VEGF) humanized IgG1 None detected 
Humira (anti-TNF) human IgG1 (phage) > 5% 
Source: E. Koren et al. [8] 
Mouse
antibody
0%
Chimeric
antibody
67%
Fully human
antibody
100%
Humanized
antibody
90%
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2. Heated competition in a growing market of MAb therapy 
Currently, therapeutic MAbs are the second largest biopharmaceutical product 
category after vaccine (Fig. 2), and the current pipelines of therapeutic MAbs in clinical 
trial contain more than 160 products in 2006 in the United States [12, 13]. This means 
that the MAb products for human therapies account for over 30% of biopharmaceuticals 
in clinical trials [12, 13]. However, at the present time, the number of target antigens 
available for MAb therapy is limited. Moreover, because substance patents of some 
target antigens are ambiguous in the application for antibody therapies, several 
biopharmaceutical companies are concurrently developing different MAb products for 
the same antigens. For these reasons, biopharmaceutical companies must assess the true 
clinical and commercial potentials (POC, proof of concept) of their products as early as 
possible. Thus, shortening of the research and developing period for their target 
products before commencing clinical trials is a key factor to compete in the growing 
market. 
 7
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Comparison of the number of biotechnology medicine pipelines between 2004 and 2008. 
Source: PhRMA [12, 13]. 
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3. Structure of antibodies 
In most higher mammals, antibodies exist in five distinct classes (IgG, IgA, IgM, 
IgD and IgE), which differ both in form (size, charge, amino acid composition, 
carbohydrate content) and functions [14]. Each antibody of the five classes consists of 
functional units of Y-shaped and bifunctional molecules with a basic symmetrical 
structure (Fig. 3), and each unit consists of four polypeptides: two identical light and 
two identical heavy chains. Each heavy chain has two regions: the constant region (CH 
region) and variable region (VH region) [15]. The subclass of an antibody is determined 
by the type of the CH region. The CH region is identical in all antibodies of the same 
subclass isotype, but differs in antibodies in different subclass isotypes. On the other 
hand, an antibody structure can be classified into two identical Fab (Fragment, antigen 
binding) and one Fc (Fragment, crystallizable) fragments by their unique functions [15]. 
These fragments are connected by the hinge region, which contributes the flexibility of 
the antibody molecule. 
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Fig. 3. Schematic structure of a functional unit of antibodies. Heavy and light chains are folded 
into domains, each containing about 110 amino acids and an intra-chain disulfide bond that 
forms a loop of 60 amino acids. VH, heavy chain variable region; VL, light chain variable region; 
CH, heavy chain constant region; CL, light chain constant region; CHO, glycoform. 
Source: Lehninger, Principles of Biochemistry, Fifth edition, 2008, [16]. 
 
IgG is adopted mainly for the human antibody therapy, and IgG antibodies have four 
subclass isotypes (IgG1, IgG2, IgG3, and IgG4, Fig. 4) [17]. Each of IgG subclass 
isotypes has various features such as stabilities and functions (Table 2), and these 
features are decisive in selecting the most suitable subclass for the target of the MAb 
therapy. IgG3 are difficult to handle for manufacturing because IgG3 does not bind to 
protein A resin, which is an affinity absorbent commonly used at the initial capture step 
during recombinant MAb purification [18]. In addition, the hinge region of human IgG3 
Variable
regions
Constant
regions
Heavy chains
Light chains
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is much longer and is prone to proteolysis than are IgG1, IgG2 and IgG4 [1]. Regarding 
IgG4, it is well known that its interchain bonds are easily broken in vivo and new 
interchain bonds can be formed between different IgG4 half-molecules [19–20]. To 
prevent the generation of such unwanted bivalent and bispecific form of IgG, IgG4P 
mutated form (Ser228Pro, EU-index numbering scheme [21]) was developed, which is 
useful for MAb therapy [22]. The IgG4PE mutated form (Ser228Pro and Leu235Glu) is 
also used to reduce the antibody-dependent cellular cytotoxicity [23]. Thus, 
concurrently, IgG1, IgG2 and IgG4 mutated form (IgG4P or IgG4PE) make up the major 
part of MAb therapeutic applications. On the other hand, light chains can also be 
divided into the constant region (CL region) and variable region (VL region). In 
mammals, there are two types of light chain, which are called κ and λ light chain. 
 
 
 
 
 
Fig. 4. Schematic diagram of the four subclasses of human IgG. Black bar represents inter-chain 
disulfide bond. 
IgG1 IgG2 IgG3 IgG4 
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A number of 3D structural data of human Fab fragments can be obtained from the 
protein structural database, Protein Data Bank (http://www.rcsb.org/pdb/). According to 
the comparison analysis using these 3D structural data, Honneger et al. showed the high 
conservation of the basic folding pattern and the core positions (Fig. 5) [24]. Besides, 
3D structural information of several IgG1 Fc fragments and one entire human IgG1 MAb 
(PDB code: 1HZH) can be obtained from the same database (Fig. 6). However, at the 
present time, there is limited 3D structural information for the Fc regions of IgG2 and 
IgG4. 
 
 
Table 2. 
Biological properties of the four human IgG subclasses 
Isotype IgG1 IgG2 IgG3 IgG4 
Molecular weight 150,000 150,000 150,000 150,000 
Hinge amino acid number 15 12 62 12 
Interchain disulfide bond number 2 4 11 2 
In vivo serum half life (days) 21–23 20–23 7–8 21–23 
Complement fixation ++ + +++ – 
Monocyte FcRI receptors binding +++ – +++ + 
FcRII receptors on neutrophilis and eosinophilis binding +++ + +++ + 
monocyte FcRIII receptors binding ++ – ++ – 
Protein A binding +++ +++ – +++ 
Strong binding +++, medium interaction ++, weak interaction +, no interaction – 
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Fig. 5. Overlay of the 3D structures of various human IgG variable regions obtained from the 
PDB database. (A), heavy chain; (B), light chain. Source: A. Honneger et al. [24]. 
 
 
 
 
 
 
Fig. 6. Crystal structure of the recombinant human κ IgG1 antibody which recognizes the 
CD4-binding site of immunodeficiency virus-1 (HIV-1) gp120 (PDB code: 1HZH) [25]. The 
overall shape is between Y and T, with a 143° angle between the major axes of the two Fab 
regions. 
(A) (B) 
(A) (B) 
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4. Platform approach for the rapid establishment of production process 
Because of the high molecular similarities of antibodies (Figs. 4, 5), in modern 
production process development of MAb products, process trains are expected to be 
compiled with generic modules that are pre-developed at scale rather than designed 
de-novo for every new product, in order to introduce target products into clinical trials 
in the shortest time possible [14]. This generalized strategy of production process 
development for every MAb product is called a platform approach [26, 27]. The 
advantage of this approach of purification process is that suitable combinations of 
chromatography steps are determined beforehand and minimal chromatography 
experiments are performed to determine details of the purification conditions. However, 
to establish an efficient platform for purification scheme, it is necessary to clarify the 
relation between retention behavior in each chromatography step and the 
physicochemical properties of MAb proteins. In particular, reliable prediction of the 
retention behavior by easily obtainable information of the target products such as amino 
acid sequences or isoelectric point values (pI values) will be useful for the rapid 
establishment of the purification scheme [28, 29]. 
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5. Hydroxyapatite 
Hydroxyapatite is a basic calcium phosphate which has the chemical formula 
Ca10(PO4)6(OH)2, and is most stable phase of calcium phosphates under ordinary 
conditions [30, 31]. It has been widely utilized as not only bone cements, bone 
replacements materials, and drug carriers but also adsorbents for liquid chromatography. 
Crystalline hydroxyapatite was introduced in 1956 by Tiselius et al. as the first type of 
hydroxyapatite adsorbent used in chromatography [32]. However, the crystallization 
method at that time led to the formation of unstable rectangular plate-shaped crystals, 
and suffered from operational limitations in chromatography such as poor flow, poor 
pressure resistance, and poor stability characteristics [33, 34]. This problem of fragility 
of the crystals was subsequently overcome by the development of ceramic-type 
hydroxyapatite [33–35]. Presently, the spherical and macroporous form of ceramic 
hydroxyapatite is widely used not only for laboratory experiments, but also for 
industrial applications as a powerful tool for the separation of proteins, nucleic acids, 
vaccine and virus [36−39]. 
In antibody manufacturing, hydroxyapatite chromatography stands out due to its 
high selectivity to remove impurities such as DNA, host-cell protein, leached protein A, 
and antibody aggregate forms, which are generated during MAb production processes 
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[35, 40, 41]. Moreover, operation of chromatography with current ceramic type 
hydroxyapatite has various potencies; it can be used at high flow rate to reduce the total 
operation time; the chromatography can be performed under neutral pH conditions; and 
it has high stability against the regeneration wash by high concentration solvent of 
sodium hydroxide. From these reasons, hydroxyapatite chromatography has been used 
as one of the efficient purification tools for MAbs [34, 38, 42, 43]. 
The adsorption mechanism of proteins to hydroxyapatite is complicated, because it 
involves concurrently both cationic exchange interaction and metal affinity interaction. 
Positively charged amino acid residues on proteins electrostatically interact with 
phosphate functional groups (P-sites) as cation-exchange. Metal affinity interaction is 
generated between calcium functional groups (C-sites) on hydroxyapatite and carboxyl 
clusters of proteins (Fig. 7) [35, 44–47]. In contrast, electrostatic repulsion between 
positively charged amino groups on proteins and C-sites, and electrostatic repulsion 
between carboxyl groups on proteins and P-sites also have been considered to affect the 
adsorption/desorption behaviors of proteins on hydroxyapatite. Furthermore, interaction 
between C-sites and the imidazole side chains of histidine residues has also been 
reported [48]. 
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Fig. 7. Protein binding to hydroxyapatite. A is a basic protein. B is an acidic protein. Calcium 
ions, phosphates, and hydroxyls indicate the surface composition of hydroxyapatite. Double 
parentheses indicate repulsion. Dotted lines indicate ionic bonds. Triangular linkages indicate 
coordination bonds [35]. 
 
Antibody purification in hydroxyapatite chromatography by sodium phosphate 
(NaPi) gradient elution has been widely used. In the recent studies, sodium chloride 
(NaCl) gradient elution showed a better performance to remove unwanted impurities 
than NaPi gradient elution (Table 3) [40, 41]. Although NaPi gradient elution 
simultaneously dissociates calcium metal affinity and cation exchange interactions, 
NaCl gradient elution is thought not to affect calcium metal affinity interactions. Thus, 
some degree of phosphate ion is thought necessary for the dissociation of metal affinity 
interactions. 
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Regarding the retention behavior of proteins in hydroxyapatite chromatography, it is 
reported that retention time shows a tendency to increase with pI value (Fig. 8), and that 
the major mode of separation would be cation exchange [49, 50]. However, the 
selectivity is distinct from classical cation exchange. Concurrently generated repulsion 
between positively charged residues and C-sites, and the geometric distribution of 
charges on the surface of proteins must be the reason for this difference of the 
selectivity between hydroxyapatite chromatography and cation exchange 
chromatography [35]. It was also shown that the denaturation of proteins (lysozyme, 
cytochrome c and pancreatic deoxyribonuclease) reduces their affinity for 
hydroxyapatite [51]. Moreover, by the study using variants of β-lactoglobulin, it is 
presumed that hydroxyapatite chromatography distinguishes a slight difference in the 
constellation of adsorption groups on a local surface of protein molecules [52, 53]. 
Table 3. 
Comparison of contaminant clearance between NaPi gradient elution and NaCl gradient elution 
in hydroxyapatite chromatography of protein A purified mouse/human chimeric IgG1 
Parameter NaPi elution NaCl elution 
Aggregate < 1% < 1% 
Leached protein A < 1 ppm < 1 ppm 
Host cell derived protein < 72 ppm < 12 ppm 
Host cell derived DNA < 7 ppm < 1 ppm 
Endotoxin < 5 EU/mL < 0.1 EU/mL 
Source: P. Gagnon et al. [41] 
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Therefore, in order to predict the retention behavior of proteins in hydroxyapatite 
chromatography, not only the information obtained from the primary structure of the 
proteins but also information of the secondary and tertiary structure is necessary. 
 
 
 
 
 
 
 
 
Fig. 8. Relation between the pI value and retention time in hydroxyapatite chromatography by 
NaPi gradient method for various proteins. 4.0 × 100 mm column. Linear gradient from 10 mM 
to 400 mM NaPi (pH 6.0) in 30 min at 0.5 ml/min [50]. 
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6. Purpose of this study 
Owing to the high similarities in IgG antibody structure, it is expected that the 
retention behavior of antibodies in hydroxyapatite chromatography can be predicted by 
the easily available information from their primary structure. The achievement of this 
prediction will reduce the development period in the early stage of process development 
for MAb therapy. In the present study, using the two elution modes generally used for 
hydroxyapatite chromatography, NaPi gradient elution (Chapter 1) and NaCl gradient 
elution methods (Chapter 2), the retention behavior of the recombinant human 
monoclonal antibodies (rhMAbs) were investigated. The determined retention times of 
the rhMAbs are discussed from the view point of the structure, particularly the 
electrostatic features of antibodies. 
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CHAPTER 1 
 
 
 
Relationship between human IgG structure  
and retention time in hydroxyapatite chromatography  
with sodium-phosphate gradient elution 
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1.1. Summary 
The aim of this study was to classify the retention time of recombinant human 
monoclonal antibodies (rhMAbs) in hydroxyapatite chromatography with 
sodium-phosphate gradient elution according to their physicochemical properties. We 
analyzed 37 rhMAbs and found that (1) the structures of both the constant and variable 
regions affected retention time, (2) the number of basic amino acid residues in the 
variable region, particularly in the heavy chain, correlated well with retention time, and 
(3) this correlation was more pronounced (e.g. r2 = 0.87 for 18 κ IgG1 rhMAbs) when 
the surface accessibility of those residues are taken into account. These findings provide 
a useful guide for investigators and purification-process developers working with 
monoclonal antibodies. 
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1.2. Introduction 
Hydroxyapatite chromatography [1] has been used for several decades in the 
purification of proteins and has recently been applied as an efficient purification tool for 
the manufacture of therapeutic monoclonal antibodies (MAbs) because it shows high 
selectivity and can be performed under neutral pH conditions [2–7]. The adsorption 
mechanism of proteins to hydroxyapatite is complicated [8−11]. Positively charged 
amino acid residues on proteins interact electrostatically with phosphate functional 
groups of hydroxyapatite (P-sites) via cation exchange. The adsorption mechanism also 
involves a metal-affinity interaction between carboxyl clusters on proteins and calcium 
functional groups of hydroxyapatite (C-sites). Whereas interactions via P-sites can be 
eliminated by an increase in ionic strength of the mobile phase, displacers such as 
phosphate or citrate ions are required for the dissociation of the metal-affinity 
interaction via C-sites. The interaction between C-sites and the imidazole side chains of 
histidine residues has also recently been discussed [12]. 
With respect to the relation between adsorption/desorption behavior of antibodies 
and their structures, chromatographic studies with various mouse MAbs have revealed 
the ability of hydroxyapatite to separate IgG idiotypes [13, 14]. With the use of a 
96-well plate screening system, Wensel et al. showed that the binding strength of 15 
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humanized IgG MAbs to hydroxyapatite varied widely, and that IgG2 MAbs exhibited 
the least overall binding compared to IgG1 and IgG4 MAbs [6]. Additionally, Schubert 
and Freitag showed using a recombinant human κ IgG1 antibody that electrostatic 
interactions via Fab (fragment, antigen binding) regions play an important role in the 
absorption to hydroxyapatite [15]. Gagnon et al. showed that papain-digested Fab 
regions of a chimeric monoclonal antibody failed to bind to the calcium-derivatized 
hydroxyapatite [16]. An understanding of the physicochemical properties of proteins 
and how they relate to the retention mechanisms of chromatographic methods would 
provide a valuable aid for the development of purification methods [17–19]. However, 
the understanding of retention behaviors of MAbs in hydroxyapatite chromatography 
according to their structural properties is still under way. 
Reliable prediction of the retention time or the peak salt concentration in column 
chromatography purification according to readily obtained information, such as the 
amino acid sequence of target MAbs, can serve as a guide for the optimization of 
loading and elution buffer conditions as well as the estimation of purity, which will 
facilitate the development of purification processes [17, 20–23]. In particular, because 
of the high similarities in protein structure of antibodies [24, 25], it is expected that 
useful parameters for the prediction of retention time of target MAbs will be identified. 
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Ishihara et al. reported that the retention behavior of human IgG MAbs on an 
SP-Sepharose FF column correlated well with the surface positive charge distribution of 
the heavy chain variable regions (VH regions) and also showed that retention behavior 
did not depend on subclass [17]. These results led to the establishment of a rational 
prediction formula for determining the NaCl concentration suitable for the elution of 
recombinant human MAbs (rhMAbs) [17]. 
In the present study, in order to classify the retention behavior of rhMAbs in 
hydroxyapatite chromatography by sodium-phosphate (NaPi) gradient elution according 
to the MAb physicochemical properties, we examined the retention times (peak sodium 
ion concentration: CNa) of 37 rhMAbs. The determined CNa values are discussed from 
the viewpoint of antibody structure, particularly amino acid sequence. 
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1.3. Experimental 
1.3.1. Recombinant human monoclonal antibodies 
All rhMAbs used in the present study were produced in suspension cultures of 
Chinese hamster ovary cells, which were transfected with vectors containing antibody 
genes cloned from human antibody-producing mice [26]. Protein A affinity 
chromatography purification of cell-culture supernatants was performed by low pH 
stepwise elution with the use of MabSelect or Protein A Sepharose FF columns (GE 
Healthcare, Buckinghamshire, UK). Further purification steps (cation-exchange, 
anion-exchange in flow-though mode, and/or hydrophobic chromatography) were 
performed as necessary to improve protein purities, which were confirmed by standard 
analytic methods. The buffer of the purified rhMAbs was exchanged to 5 mM NaPi (pH 
6.8) with the use of Amicon Ultra-4 10K molecular-weight cutoff centrifugal filter units 
(Millipore, Billerica, MA, USA), and the antibody concentration was adjusted to 250 
µg/mL. 
The classification of the 37 rhMAbs according to their physicochemical properties is 
shown in Table 1.1. The IgG3 rhMAb subclass was not analyzed in this study because 
IgG1, IgG2, and IgG4 comprise the majority of MAbs used for therapeutic applications 
[27]. The 10 IgG4 rhMAbs (MAbs A-4, B-4, C-4, D-4, and 1 to 6) are also classified 
 31
according to inserted point mutations: 3 wild-type IgG4 MAbs, 1 IgG4P mutated MAb, 
and 6 IgG4PE mutated MAbs. The IgG4P MAb contains an amino acid point mutation of 
Ser228Pro in the heavy chain of IgG4 (EU-index numbering scheme [28] used 
throughout) to prevent half-antibody formation [29]. The IgG4PE MAbs additionally 
contain a Leu235Glu point mutation in the heavy chain to reduce antibody-dependent 
cytotoxicity [30]. Twelve rhMAbs, from MAb A-1 to MAb D-4, comprise 4 sets of 3 
subclass isotypes. Thus, the amino acid sequences of the light chains and VH regions in 
each set are identical, but their subclass is different (IgG1, IgG2, IgG4, or IgG4PE). The 
MAbs D-1, D-2, and D-4 contain an N-glycan structure in each of the VH regions. The 
19 IgG1 rhMAbs (MAbs A-1, B-1, C-1, D-1, and E to S) and all of the IgG2 and IgG4 
rhMAbs are classified as κ IgG antibodies. The 4 rhMAbs from MAb T to MAb W 
consist of λ light chains, and these light-chain constant regions are classified as IGLC3, 
IGLC1, IGLC2, and IGLC1, respectively, according to the international 
ImMunoGeneTics (IMGT) nomenclature rules [31, 32]. The germline families of the VH 
and light chain variable regions (VL regions) for each rhMAb classified by the IMGT 
rules are also listed in Table 1.1. 
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Table 1.1. 
Physicochemical properties of rhMAbs and peak retention time in NaPi gradient hydroxyapatite chromatography 
rhMAb Subclass 
Type of  
light chain 
Germline 
family of  
VH regions
a) 
Germline 
family of  
VL regions
a) 
Isoelectric  
point (pI) 
Binding 
site of 
N-glycan  
Peak 
phosphate 
concentration, 
CPhos (mM) 
Peak 
sodium ion 
concentration, 
CNa (mM)
b) 
MAb A-1 IgG1 κ IGHV6 IGKV1 8.91 CH2 189 308 
MAb A-2 IgG2 κ IGHV6 IGKV1 8.54 CH2 149 243 
MAb A-4 IgG4PE
c) κ IGHV6 IGKV1 8.05 CH2 169 275 
MAb B-1 IgG1 κ IGHV1 IGKV4 8.91 CH2 172 280 
MAb B-2 IgG2 κ IGHV1 IGKV4 8.58 CH2 121 196 
MAb B-4 IgG4PE
c) κ IGHV1 IGKV4 8.10 CH2 148 242 
MAb C-1 IgG1 κ IGHV1 IGKV1 8.86 CH2 155 253 
MAb C-2 IgG2 κ IGHV1 IGKV1 8.26 CH2 86 139 
MAb C-4 IgG4 κ IGHV1 IGKV1 7.94 CH2 124 202 
MAb D-1 IgG1 κ IGHV1 IGKV3 8.54 VH, CH2 e) 117 190 
MAb D-2 IgG2 κ IGHV1 IGKV3 7.94 VH, CH2 e) 61 99 
MAb D-4 IgG4 κ IGHV1 IGKV3 7.43 VH, CH2 e) 77 125 
MAb E IgG1 κ IGHV1 IGKV1 8.53 CH2 149 242 
MAb F IgG1 κ IGHV3 IGKV1 8.95 CH2 143 233 
MAb G IgG1 κ IGHV3 IGKV1 9.00 CH2 166 271 
MAb H IgG1 κ IGHV3 IGKV1 8.71 CH2 156 254 
MAb I IgG1 κ IGHV3 IGKV3 8.94 CH2 177 289 
MAb J IgG1 κ IGHV3 IGKV6 8.83 CH2 153 250 
MAb K IgG1 κ IGHV3 IGKV6 8.73 CH2 169 275 
MAb L IgG1 κ IGHV4 IGKV3 8.88 CH2 148 241 
MAb M IgG1 κ IGHV4 IGKV3 8.97 CH2 152 248 
MAb N IgG1 κ IGHV4 IGKV3 8.85 CH2 147 239 
MAb O IgG1 κ IGHV4 IGKV3 8.61 CH2 168 274 
MAb P IgG1 κ IGHV4 IGKV3 8.88 CH2 158 257 
MAb Q IgG1 κ IGHV4 IGKV3 9.01 CH2 160 262 
MAb R IgG1 κ IGHV4 IGKV1 not tested CH2 129 210 
MAb S IgG1 κ IGHV5 IGKV1 8.88 CH2 153 249 
MAb T IgG1 λ IGHV1 IGLV1 8.85 CH2 125 203 
MAb U IgG1 λ IGHV3 IGLV7 8.97 CH2 137 223 
MAb V IgG1 λ IGHV7 IGLV3 not tested CH2 108 176 
MAb W IgG1 λ IGHV3 IGLV1 not tested CH2 149 242 
MAb 1 IgG4 κ IGHV3 IGKV3 not tested CH2 130 211  
MAb 2 IgG4P
d) κ IGHV4 IGKV3 not tested CH2 129 210 
MAb 3 IgG4PE
c) κ IGHV3 IGKV1 not tested CH2 116 188 
MAb 4 IgG4PE
c) κ IGHV3 IGKV1 not tested CH2 117 190 
MAb 5 IgG4PE
c) κ IGHV4 IGKV1 not tested CH2 141 229 
MAb 6 IgG4PE
c) κ IGHV4 IGKV3 not tested CH2 124 201 
a)Germline family was determined according to the immunogenetics nomenclature rules [31, 32]. 
b)CNa can be calculated according to the following equation; CNa = 1.633 * CPhos - 0.584.
 
c)Ser228Pro and Leu235Glu  mutated forms of the IgG heavy chain . 
d)Ser228Pro mutated form of the IgG4 heavy chain. 
e)Presence of N-glycan in the VH regions was confirmed by sugar-chain analysis. 
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1.3.2. Instrumentation and materials for chromatography experiment 
Chromatography experiments were performed on an Alliance HPLC Workstation 
(Waters, Milford, MA, USA). Ceramic hydroxyapatite type II with an average bead size 
diameter of 20 µm (BioRad Laboratories, Hercules, CA, USA) was used as the 
chromatography medium and was packed into a glass column of 3-mm internal 
diameter and 50-mm height (Kyoshin Kogyo, Tokyo, Japan). Although type I 
hydroxyapatite shows high binding capacity compared to type II hydroxyapatite [33] 
and is widely used in industrial-scale IgG antibody applications, type II is superior in 
resolution to type I. Both types are also known to show similar elution characteristics. 
In addition, 40-µm or 80-µm bead size is commonly used for industrial-scale 
manufacturing to prevent high back-pressure. In the present study, we used type II 
hydroxyapatite of 20-µm bead size to obtain high resolution. Sodium phosphate dibasic 
dodecahydrate (Junsei Chemical, Tokyo, Japan), sodium phosphate monobasic 
dihydrate (Kokusan Chemical, Tokyo, Japan), and purified water were used to prepare 
chromatography buffers. All reagents used in this study were of analytical grade. 
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1.3.3. Hydroxyapatite chromatography 
The hydroxyapatite column was equilibrated with 5 mM NaPi, pH 6.8 (buffer A). 
The flow rate was 0.35 mL/min. Samples were loaded onto the column at 0.035 mg 
rhMAb/mL hydroxyapatite. The sample injection volume was 50 µL. After washing the 
column with buffer A for 5 min, elution was performed for 30 min with a linear gradient, 
from buffer A to 400 mM NaPi, pH 6.8 (buffer B). The column was regenerated with 
buffer B for 2 min. To prevent strong effects of phosphate concentration on pH, the pH 
values of both chromatography buffers were adjusted with a calibrated pH meter by 
mixing 5 mM (or 400 mM) solution of sodium phosphate dibasic and the solution of 
sodium phosphate monobasic of the same concentration. Chromatographic runs were 
performed at 25°C, and the column effluent was monitored at 215 nm and 280 nm. The 
baseline absorbance at 215 nm increased during gradient elution, and the correlation 
formula between run time and phosphate concentration of the column effluent could be 
calculated. The peak phosphate concentration (CPhos) for each rhMAb was determined 
according to the correlation formula and the peak retention time. The phosphate 
concentration and the sodium ion concentration in the prepared buffers were 4.951 mM 
and 7.502 mM for buffer A, and 400.0 mM and 652.8 mM for buffer B. Thus, the CNa 
value can be calculated according to the following equation; 
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0.584C1.633C PhosNa −×=  
Chromatography experiments for each rhMAb sample were conducted in duplicate, 
and the average of the CNa values was used for interpretation. Control rhMAb (MAb 
A-1) was injected every 10 runs to confirm the validity of column reuse. 
 
1.3.4. Measurement of isoelectric point 
To determine isoelectric point (pI) values for the rhMAbs, isoelectric focusing was 
performed with the use of an Ampholine PAGplate (GE Healthcare) at pH 3.5−9.5. The 
buffer of the samples was exchanged to purified water, and 25 µg was loaded onto the 
gel. The running conditions were 90 min at 50 mA and 30 W. After electrophoresis, gels 
were stained with Coomassie brilliant blue. The pI value of each rhMAb was calculated 
with the use of the calibration curve for marker proteins included in the Broad pI kit 
(GE Healthcare). Some of the analyzed rhMAbs showed several bands in the gel. In 
these cases, the pI value of the predominant band was used. 
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1.3.5. Relative solvent accessibility 
We searched the protein structure database RCSB Protein Data Bank 
(http://www.rcsb.org/pdb/) for antibodies and antibody fragments with high amino acid 
sequence homology to the rhMAbs used in this study. For the antibodies and antibody 
fragments detected, the absolute surface area of each amino acid residue was calculated 
with the use of the Digital Shape Sampling and Processing program [34]. The relative 
solvent accessibility (RSA) value for each amino acid residue was defined as the ratio of 
the absolute surface area of the residue observed in the three-dimensional structure to 
that observed in the extended tripeptide (Ala-X-Ala) conformation [35]. The 
extended-state absolute surface area values were the same as those reported by Ahmad 
et al. in Table 1.2 [35]. The RSA of each amino acid residue for the rhMAbs used in this 
study was estimated by calculating the mean of the RSA values of the positionally 
equivalent amino acid residue in the homologous antibodies and antibody fragments. 
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Table 1.2. 
The absolute surface area values in extended tripeptide (Ala-X-Ala) 
conform ation for each of the 20 mino acids 
Amino acid 
residue 
Absolute surface 
area values in 
extended tripeptide 
(Å2) 
 
Amino acid 
residue 
Absolute surface 
area values in 
extended tripeptide 
(Å2) 
Alanine 110.2   Methionine 200.1  
Aspartate 144.1   Aspartate 146.4  
Cysteine 140.4   Proline 141.9  
Glutam ine 174.7   Glutamate 178.6  
Phenylalanine 200.7   Arginine 229.0  
Glycine 78.7   Serine 117.2  
Histidine 181.9   Threonine 138.7  
Isoleucine 185.0   Valine 153.7  
Lysine 205.7   Tryptophan 240.5  
Leucine 183.1   Tyrosine 213.7  
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1.4. Results and discussion 
1.4.1. Hydroxyapatite chromatography of 37 rhMAbs 
Hydroxyapatite chromatography experiments of the 37 rhMAbs by NaPi gradient 
elution were performed. These rhMAbs differed in their variable regions, heavy chain 
subclass, and light chain type (Table 1.1). Twelve rhMAbs, from MAb A-1 to MAb D-4, 
comprised 4 sets of variable domain-identical antibodies. The MAbs of each set differed 
only in subclass (IgG1, IgG2, IgG4, or IgG4PE). Amino acid sequences of the variable 
regions of the 23 IgG1, 4 IgG2, and 10 IgG4 (including 1 IgG4P and 6 IgG4PE) rhMAbs 
showed sufficient variety for the present study. This is also shown in Table 1.1 as 
variety of the germline families of the VH and VL regions. 
The CNa and CPhos values of individual rhMAbs are also shown in Table 1.1. The 
calculated standard deviation of the CNa values for the control rhMAbs was 1.8 mM, 
and the coefficient of variation was 0.6%, indicating the high reproducibility of this 
method. 
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1.4.2. Relation between antibody structure and retention time 
The obtained CNa values are compared in Fig. 1.1. An elution order according to 
subclass (IgG2 < IgG4, IgG4PE < IgG1) was observed for each of the 4 sets of variable 
domain-identical rhMAbs (MAbs A-1 to D-4). The observed elution order for subclass 
isotypes was different from that in cation-exchange chromatography, where elution 
behavior does not depend on subclass [17]. The elution order in hydroxyapatite 
chromatography was observed even for rhMAbs containing an N-glycan in each of the 
VH regions (MAbs D-1, D-2, and D-4). Similarly, point mutations in the IgG4 rhMAbs 
did not change the elution order. In addition, the λ IgG1 rhMAbs (MAbs T to W; 
average CNa being 211 mM) tended to elute earlier than the κ IgG1 rhMAbs (average 
CNa being 257 mM). In relation to the variable regions, variation in the CNa values was 
also observed among the subclass-identical rhMAbs with the same light chain type. 
From these results, we concluded that all aspects of subclass, light chain type, and 
variation of amino acid sequence in the variable regions must be taken into account to 
classify the CNa values of human IgG MAbs in the NaPi gradient hydroxyapatite 
chromatography. Interestingly, MAb D-1, containing an N-glycan in each of the VH 
regions, showed the smallest CNa value among all of the κ IgG1 rhMAbs, suggesting that 
the presence of N-glycan in the VH regions also affects the retention behavior.
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Fig. 1.1. Peak sodium ion concentration values of rhMAbs in hydroxyapatite chromatography. 
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1.4.3. Relation between acidic and basic amino acid residues and 
retention time 
The CNa or CPhos values for 34 rhMAbs (excluding MAbs D-1 to D-4) were compared 
according to the number of the following acidic and basic amino acid residues in the 
entire antibody: arginine (Arg), lysine (Lys), histidine (His), glutamate (Glu), and 
aspartate (Asp). Figure 1.2 shows a relatively higher correlation between CNa and the 
number of basic residues (correlation coefficient: r2 = 0.50 for Arg, Lys, and His; Fig. 
1.2A) than between CPhos and the number of acidic residues (r
2 = 0.00 for Glu and Asp; 
Fig. 1.2B) or between CNa and the number of acidic and basic residues (r
2 = 0.24 for Arg, 
Lys, His, Glu, and Asp; Fig. 1.2C). This result suggested that the number of basic 
residues is correlated with retention behavior. 
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Fig. 1.2. Relation between the numbers of acidic and basic amino acid residues in the entire 
antibody molecule and peak sodium ion or phosphate concentration in hydroxyapatite 
chromatography for 34 rhMAbs(excluding MAbs D-1, D-2, and D-4). (A) Basic amino acid 
residues (Arg, Lys, and His); (B) acidic amino acid residues (Glu and Asp); (C) acidic and basic 
amino acid residues (Arg, Lys, His, Glu, and Asp). Correlation coefficient in each panel was 
calculated using the values for all 34 rhMAbs. 
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The relation between pI and CNa was investigated for the 25 rhMAbs (MAbs A-1 to 
C-4, E to Q, and S to U) (Fig. 1.3). The pI value provides a simple indication of the net 
charge of proteins, and the chromatographic behavior of proteins is usually explained by 
their pI values and the mobile-phase pH in ion-exchange chromatography. The result of 
the present study showed a weak correlation (r2 = 0.43). No significant correlations were 
found, however, among members of each antibody group (κ IgG1, κ IgG2, etc.). Thus, it 
was indicated that the retention behavior of rhMAbs in hydroxyapatite chromatography 
cannot be determined simply by net charge properties. 
 
 
 
 
 
 
 
 
Fig. 1.3. Plots of isoelectric point (pI) values versus peak sodium ion concentration values for the 
25 rhMAbs. pI values were determined by isoelectric focusing. 
80
120
160
200
240
280
320
7.5 8.0 8.5 9.0 9.5
pI
P
ea
k
 s
od
iu
m
 io
n 
co
nc
en
tr
at
io
n
 (
m
M
)_
_
kappa IgG1
kappa IgG2
kappa IgG4
kappa IgG4PE
lambda IgG1
45 
Although the metal-affinity interaction between carboxyl clusters of acidic residues 
on proteins and C-sites has been suggested to be involved in antibody adsorption, the 
number of acidic residues did not show a correlation with CPhos (Fig. 1.2B). In most 
cases, a low concentration of phosphate ion (ca. 5–15 mM) is necessary for the elution of 
IgG antibodies in hydroxyapatite chromatography with NaCl gradient elution [33]. 
However, the CPhos value of antibodies with NaPi gradient elution (ca. 60–190 mM in the 
present study, Table 1.1) was much higher than that required for NaCl gradient elution. 
These results suggested that the metal-affinity interaction is already eliminated before 
the dissociation of cation exchange interactions between positively charged amino acid 
residues and P-sites [4, 33]. The involvement of the metal-affinity interactions in the 
adsorption of rhMAbs onto hydroxyapatite is described in CHAPTER 2.  
Next, antibody structure (subclass, light chain type, and VH or VL regions) was taken 
into consideration in an attempt to identify relevant parameters to correlate better with 
CNa. Table 1.3 shows the r
2 values calculated between CNa and various combinations of 
the number of acidic and basic residues in one or both of the VH and VL regions of the 18 
κ IgG1 rhMAbs (excluding MAb D-1). The results indicated that the number of basic 
residues (Arg, Lys, and His) in the VH regions showed a stronger correlation (r
2 = 0.55) 
with CNa than the number of basic residues in the VL regions (r
2 = 0.00) or the number of 
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basic residues in both the VH and VL regions (r
2 = 0.46). This tendency was also 
observed for the 4 λ IgG1 rhMAbs, the 3 κ IgG2 rhMAbs, and the 9 κ IgG4 rhMAbs, 
including IgG4P and IgG4PE rhMAbs (data not shown). From these results, we 
concluded that the retention behavior of subclass-identical rhMAbs with same type of 
light chains in NaPi gradient hydroxyapatite chromatography depended on the properties 
of the basic amino acid residues in the VH regions more than those in the VL regions. 
 
 
Table 1.3. 
Correlation coefficient (r2) between the number of acidic and basic residues in one or both of the 
VH and VL regions and peak sodium ion concentration for the 18 κ IgG1 rhMAbs 
  Arg Lys His  Glu Asp  
Basic amino 
acid residue 
(Arg, Lys, His) 
 
Acidic and 
basic residues 
(Arg, Lys, His, 
Glu, Asp) 
VH 
0.26  0.05  0.21   0.08  0.03   0.55  0.39 
VL 
0.00  0.00  0.00   0.05  0.00   0.00  0.03 
VH + VL 
0.27  0.04  0.13   0.14  0.01   0.46  0.40 
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1.4.4. Contribution of variable region to retention time 
To obtain a more relevant correlation between the number of basic amino acid 
residues and CNa, the surface accessibility of each basic residue was taken into account. 
The solvent-accessible surface area of each amino acid residue in a protein can be 
computed with bioinformatics software when three-dimensional structural information of 
the protein can be obtained [34]. The surface accessibility of the side chain of each 
amino acid residue is represented as the RSA percentage by calculating the ratio of the 
absolute surface area of the residue of the three-dimensional structure to that observed in 
the extended tripeptide (Ala-X-Ala) conformation [35]. 
Each of the VH and VL regions of human IgG is known to share structural similarity 
[25]. Although the three-dimensional structures of the rhMAbs used in the present study 
have not yet been determined, they can be estimated reliably by homology modeling of 
the structures of antibodies and antibody fragments with similar amino acid sequences. 
In the present study, the side chain RSA values of each basic residue in the variable 
regions for all of the rhMAbs were estimated, and the correlation between the number of 
basic residues with various surface accessibility cut-off values and CNa was investigated. 
For the 18 κ IgG1 rhMAbs (MAbs A-1, B-1, C-1, and E to S), the plot of CNa against 
the number of basic residues with > 40% RSA in the VH regions (r
2 = 0.87; Fig. 1.4B) 
48 
showed a higher correlation coefficient compared to that in the plot that did not take 
surface accessibility of each basic residue into account (r2 = 0.55; Fig. 1.4A). Similarly, 
with respect to the 4 λ IgG1 rhMAbs (MAbs T to W), the correlation was also improved 
(from r2 = 0.94 to r2 = 0.99; Figs. 1.4A, B) when surface accessibility was considered. 
This tendency was also observed for the IgG2 rhMAbs (r
2 improved from 0.95 to 1.00) 
and the IgG4 rhMAbs (including IgG4P and IgG4PE mutated forms; r
2 improved from 
0.25 to 0.80). These results indicated that the retention behavior of subclass-identical 
rhMAbs consisting of same type of light chains showed a clear correlation with the 
number of surface-exposed basic amino acid residues in the VH regions in 
hydroxyapatite chromatography with NaPi gradient elution. It was thus considered that 
the main interaction mechanism between rhMAbs and hydroxyapatite, which contributed 
to the retention behavior, was cation exchange. 
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Fig. 1.4. Comparison between the number of basic amino acid residues (Arg, Lys, and His) in the 
VH regions and the peak sodium ion concentration for the 18 κ IgG1 rhMAbs (MAbs A-1, B-1, 
C-1, and E–S), 1 κ IgG1 rhMAb containing an N-glycan in each of the VH regions (MAb D-1), 
and 4 λ IgG1 rhMAbs (MAbs T–W). Numbers of basic amino acid residues were counted on one 
side of the 2 variable domains. Peak sodium ion concentration versus the number of (A) basic 
amino acid residues and (B) basic amino acid residues with > 40% relative solvent accessibility 
(RSA). (C) Correlation coefficients between peak sodium ion concentration and the number of 
high surface-accessible basic amino acid residues in the VH regions, with various lower limits of 
RSA (0%–60%) for the 18 κ IgG1 rhMAbs. 
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Figure 1.4C shows the correlation coefficients between CNa and the number of basic 
amino acid residues in the VH regions, with different lower limits of RSA for the 18 κ 
IgG1 rhMAbs. The results indicated that the basic residues on the protein surface are 
involved in the interaction with hydroxyapatite; the number of basic residues with > 40% 
RSA showed the highest correlation coefficient. 
We mentioned that the number of basic residues in the VH regions showed a stronger 
correlation with CNa than the ones in the VL or the whole (VH and VL) regions (Table 1.3). 
To investigate the differential contribution of the two regions to the elution behavior, we 
examined the correlation between the number of basic residues with > 40% RSA in 
whole (VH and VL) regions and CNa for the 18 κ IgG1 rhMAbs. The calculated correlation 
coefficient (r2 = 0.68; not shown) was again smaller than that for the VH regions only r
2 
= 0.87; Fig. 1.4B). The differential contribution from the VH and VL regions may be due 
to some differential structural geometry of binding surfaces of the two regions. 
The correlation was slightly higher when the number of His residues was included in 
the calculation of the r2 value (for the 18 κ IgG1 rhMAbs, r
2 = 0.55 vs. 0.53 in Fig. 1.4A; 
r
2 = 0.87 vs. 0.81 in Fig. 1.4B). Histidine has a weak basic imidazole group in the side 
chain, and the pKa value of the imidazole group is 5.97. Thus, the imidazole side chains 
are expected to be positively charged partially (13%, according to the 
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Henderson–Hasselbalch equation) in the buffer conditions used in the present study (pH 
6.8). The better correlation when the His residues were taken into account may be 
ascribed to this partial positive charges on the side chains of His. Although His residues 
may also be involved in the adsorption to C-sites on hydroxyapatite via the metal affinity 
interaction [12], it is unlikely, however, that such a metal-affinity interaction between 
His residues and C-sites would be sustained at the high concentration of displacer 
phosphate ion at elution. Whatever the reason, it may be appropriate to take the number 
of the surface-distributed His residues into account in interpreting the retention behavior 
of rhMAbs in NaPi gradient hydroxyapatite chromatography. 
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1.4.5. Contribution of constant region to retention time 
Figures 1.4A and 1.4B showed that the λ IgG1 rhMAbs (MAbs T to W) did not 
follow the correlation curve of the κ IgG1 rhMAbs, despite the sufficient structural 
similarity of the λ and κ framework regions [25]. Because the number of basic amino 
acid residues was counted only in the VH region, this differential retention behavior was 
thought to be caused by differences in the number of basic residues in the light chain 
constant (CL) region between λ and κ IgG1 rhMAbs. However, the number of basic 
amino acid residues with > 40% RSA in the λ and κ CL regions (λ CL being IGLC1, 
IGLC2, and IGLC3 according to the IMGT nomenclature rules) was the same (seven). 
With respect to the difference of λ and κ antibodies, it is known that λ chains exhibit 
much wider range of the elbow angle (the angle between the variable and constant 
domains of light chain) than κ chains, and the flexibility of the light chain is thought to 
affect ligand binding [36, 37]. Such a difference in conformational flexibility between λ 
and κ antibodies may influence the accessibility of the binding sites to hydroxyapatite. 
In Fig. 1.5, the number of basic residues with > 40% RSA in the VH region is plotted 
against CNa for the 37 rhMAbs. When these 37 rhMAbs were classified according to 
their subclass and type of light chain, each group showed a linear correlation with a 
similar slope. Therefore, the CNa values of rhMAbs on hydroxyapatite with NaPi gradient 
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elution can be classified by the type of constant regions (subclass, type of light chains) 
and the number of surface-distributed basic amino acid residues in the VH regions. In 
relation to IgG4 rhMAb and IgG4 mutated forms (IgG4P and IgG4PE), the correlation 
curve showed a high correlation coefficient value (r2 = 0.80). Although the Ser228Pro 
and Leu235Glu point mutations are known to be effective in preventing half-antibody 
formation and in reducing antibody-dependent cytotoxicity [29, 30], these mutations did 
not influence the retention behavior. 
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Fig. 1.5. Comparison between the number of basic amino acid residues (Arg, Lys, and His) with 
> 40% RSA in the VH region and peak sodium ion concentration for the 37 rhMAbs. Correlation 
curves, from the top, were calculated for the 18 kappa IgG1 rhMAbs, 9 IgG4 rhMAbs (including 
IgG4P and IgG4PE rhMAbs), 4 lambda IgG1 rhMAbs, and 3 IgG2 rhMAbs. The rhMAbs 
containing an N-glycan in each of the VH regions (MAbs D-1, D-2, and D-4) were not included 
in the calculation of the correlation curves. 
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In clear contrast to results of cation-exchange chromatography with rhMAbs [17], 
the retention behavior with NaPi gradient hydroxyapatite chromatography was affected 
by antibody subclass. The reasons for the differential interaction according to subclass 
may include the differential distribution of basic amino acid residues on the heavy chain 
constant regions, which will become clear when three-dimensional structural information 
for IgG2 and IgG4 antibodies becomes available. 
 
1.4.6. Effect of N-glycan linked to VH region on retention time 
The MAb D-1, which is classified as κ IgG1 and contains an N-glycan in each of the 
VH regions, eluted the earliest among the 19 κ IgG1 rhMAbs (Fig. 1.1). In addition, MAb 
D-1 showed a clear deviation from the correlation curve of the 18 κ IgG1 rhMAbs 
without N-glycan, (Fig. 1.4B). This deviation of rhMAbs with N-glycan in their VH 
regions from the correlation curves of their subclass-identical rhMAbs was also observed 
for MAbs D-2 and D-4 (Fig. 1.5). According to amino acid sequence analysis and 
structural homology modeling, the glycosylation sites of MAbs D-1, D-2, and D-4 are 
estimated to be located at the tips of the VH regions, which are between the second and 
third complementarity-determining regions. This suggests that the presence of N-glycan 
in the VH regions inhibits the interaction of this region with hydroxyapatite. In addition, 
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Kishino et al. reported that various glycoforms of human serum alpha1-acid glycoprotein 
can be separated by phosphate gradient hydroxyapatite chromatography and that 
glycoforms with highly branched glycan chains tended to elute earlier than those with 
poorly branched glycan chains [38]. Furthermore, Melcher et al. reported that among 
mutants of human lysozyme, the one with the highest carbohydrate content eluted first 
from hydroxyapatite [39]. These reports are in agreement with our present observations 
and suggest that N-glycan in the VH regions of MAbs D-1, D-2, and D-4 interferes with 
binding to hydroxyapatite. 
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1.5. Concluding remarks 
A survey of hydroxyapatite retention of 37 structurally well-characterized IgG 
rhMAbs using NaPi gradient elution revealed that the retention time (CNa) can be 
classified according to the subclass (IgG1 > IgG4 > IgG2), type of light chain (κ IgG > λ 
IgG), and the number of surface-distributed basic amino acid residues in the VH regions 
(positive linear relation with CNa). Though it was therefore supposed that the main 
retention mechanism of rhMAbs on hydroxyapatite was cation exchange interaction, the 
result that subclass affected the retention behavior was different from a simple 
cation-exchange chromatography. These findings should be helpful to investigators and 
purification-process developers working with antibodies. 
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CHAPTER 2 
 
 
 
Relationship between human IgG structure  
and retention time in hydroxyapatite chromatography  
with sodium-chloride gradient elution 
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2.1. Summary 
Accurate prediction of the elution tendency of monoclonal antibodies in column 
chromatography would be beneficial for the efficient setup of purification procedures. 
Hydroxyapatite chromatography experiments using 37 recombinant human monoclonal 
antibodies were performed by sodium-chloride gradient elution with 5 mM sodium 
phosphate to correlate the retention times with antibody structures (subclass and light 
chain isotypes). The contribution of metal affinity interactions in the interaction of 
antibodies with hydroxyapatite was investigated by (1) eliminating 5 mM sodium 
phosphate in buffers, (2) comparing sodium-chloride vs. sodium-phosphate gradient 
elutions, and (3) using IgG4 antibodies with a leucine → glutamate mutation. By using 
antibodies of different subclasses but with identical Fab regions, the elution behavior in 
sodium-chloride elution could be classified by subclass and type of light chain. It is 
considered that the retention of monoclonal antibodies to hydroxyapatite is affected by 
the cooperation of phosphoryl cation exchange and metal affinity interactions. The 
contribution of the metal affinity interactions is greater in the sodium-chloride gradient 
elution method than in the sodium-phosphate gradient elution method. 
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2.2. Introduction 
Hydroxyapatite chromatography [1] has been applied as an efficient tool for the 
purification of recombinant monoclonal antibodies (rMAbs) because it offers high 
selectivity and can be performed under neutral pH conditions [2–5]. Two fundamentally 
different interaction mechanisms are mainly involved in hydroxyapatite chromatography 
of proteins [6–9]: (1) a phosphoryl cation exchange interaction between positively 
charged amino acid residues on proteins and phosphate functional groups of 
hydroxyapatite (P-sites), and (2) a calcium-metal-affinity interaction between carboxyl 
clusters on proteins and calcium functional groups of hydroxyapatite (C-sites). This 
complexity of the interaction mechanisms makes it difficult to predict or classify 
retention behavior. 
Diverse studies have been conducted on the interaction of rMAbs and hydroxyapatite. 
By a high-throughput screening system using 96-well plates dispensed with 
hydroxyapatite resin, Wensel et al. examined the binding of 15 humanized MAbs under 
various combinations of sodium phosphate (NaPi), sodium chloride (NaCl), and pH [10]. 
They showed that there was a wide variation in MAb binding strengths to hydroxyapatite, 
and that the logarithm of the partition coefficients of MAbs to hydroxyapatite is linearly 
correlated with pH, log[sodium chloride], and log[total phosphate]. In addition, there 
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were no consistent trends in binding with regard to antibody characterization parameters 
(e.g., light chain isotype, CDR classification), except that IgG2 MAbs showed least 
overall binding. Schubert and Freitag used a recombinant human κ IgG1 antibody and 
electrostatic modeling techniques to demonstrate that electrostatic interactions via Fab 
(fragment, antigen binding) regions play an important role in the absorption to 
hydroxyapatite [11]. Furthermore, Gagnon et al. showed that papain-digested Fab 
regions of a chimeric MAb failed to bind to calcium-derivatized hydroxyapatite [12]. On 
the other hand, in our previous study, we examined the retention behavior of 
recombinant human MAbs (rhMAbs), which included antibodies of different subclasses 
but with identical Fab regions, in hydroxyapatite chromatography by the NaPi gradient 
method. We showed that the retention time can be classified by subclass (IgG2 < IgG4 < 
IgG1), type of light chain (λ IgG < κ IgG), and the number of surface distributed basic 
amino acid residues (arginine, lysine, and histidine) in the heavy chain variable regions 
(VH regions) [13]. 
In this study, we examined the retention times (peak NaCl concentration values 
(CNaCl)) of 37 rhMAbs to correlate the retention behavior of rhMAbs with the antibody 
structures in hydroxyapatite chromatography by NaCl gradient elution. The CNaCl values 
obtained were compared with the retention times by NaPi gradient elution to improve 
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our understanding of the interaction mechanisms between rhMAbs and hydroxyapatite. 
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2.3. Experimental 
2.3.1. Recombinant human monoclonal antibodies 
All rhMAbs used in this study were identical to those used in our previous study of 
NaPi gradient elution experiments [13]. They were produced in suspension cultures of 
Chinese hamster ovary cells, which were transfected with vectors containing antibody 
genes cloned from human antibody-producing mice [14]. Protein A affinity 
chromatography purification of cell culture supernatants was performed by low pH 
stepwise elution using MabSelect or Protein A Sepharose FF columns (GE Healthcare, 
Buckinghamshire, UK). Further purification steps (cation-exchange, anion-exchange in 
flow-though mode, and/or hydrophobic chromatography) were performed as necessary 
to improve protein purity. The purified rhMAbs were buffer-exchanged to 5 mM NaPi 
(pH 6.8) with the use of Amicon Ultra-4 10K molecular-weight cutoff centrifugal filter 
units (Millipore, Billerica, MA, USA), and the antibody concentration was adjusted to 
250 µg/mL. 
The classification of the 37 rhMAbs according to their physicochemical properties is 
shown in Table 2.1. IgG3 rhMAb was not used because IgG3 antibody is difficult to 
handle for manufacturing and therapeutic purposes due to its low binding capacity on the 
protein A adsorbent and to its high sensitivity to proteolysis [15, 16]. The 10 IgG4 
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rhMAbs (MAbs A-4, B-4, C-4, D-4, and 1 to 6) were also classified according to inserted 
point mutations: three wild-type IgG4 MAbs, one IgG4P mutated MAb, and six IgG4PE 
mutated MAbs. The IgG4P MAb contains an amino acid point mutation of Ser228Pro in 
the heavy chain of IgG4 (EU-index numbering scheme [17] used throughout) to prevent 
half-antibody formation [18]. The IgG4PE MAbs additionally contain a Leu235Glu point 
mutation in the heavy chain to reduce antibody-dependent cellular cytotoxicity [19]. 
Twelve rhMAbs from MAb A-1 to MAb D-4 comprise four sets of three subclass 
isotypes. Thus, the amino acid sequences of the light chains and VH regions in each set 
are identical, but their subclasses are different (IgG1, IgG2, IgG4, or IgG4PE). MAbs D-1, 
D-2, and D-4 contain an N-glycan structure in each of the VH regions. The glycosylation 
site is estimated to be located on the tips of the VH regions between the second and third 
complementarity determining regions by amino acid sequence analysis and structural 
homology modeling. The 19 IgG1 rhMAbs (MAbs A-1, B-1, C-1, D-1, and E to S) and 
all of the IgG2 and IgG4 rhMAbs are classified as κ IgG antibodies. The four rhMAbs 
from MAb T to MAb W consist of λ light chains, and these light-chain constant regions 
are classified as IGLC3, IGLC1, IGLC2, and IGLC1, respectively, according to the 
international ImMunoGeneTics (IMGT) nomenclature rules [20, 21]. The germline 
families of the VH and light chain variable regions (VL regions) for each rhMAb 
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classified by the IMGT rules are also listed in Table 2.1. 
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Table 2.1. 
Physicochemical properties of rhMAbs and retention time in hydroxyapatite chromatography by NaPi or NaCl gradient elution 
rhMAb Subclass 
Type of 
light chain 
Germline family 
of VH region
a) 
Germline family 
of VL region
a) 
Binding 
site of 
N-glycans 
CNaPi, 
NaPi gradient 
(mM)b) 
CNaCl, 
NaCl gradient 
(mM)c) 
MAb A-1 IgG1 κ IGHV6 IGKV1 CH2 308 685 
MAb A-2 IgG2 κ IGHV6 IGKV1 CH2 243 394 
MAb A-4 IgG4PE
d) κ IGHV6 IGKV1 CH2 275 1023 
MAb B-1 IgG1 κ IGHV1 IGKV4 CH2 280 623 
MAb B-2 IgG2 κ IGHV1 IGKV4 CH2 196 373 
MAb B-4 IgG4PE
d) κ IGHV1 IGKV4 CH2 242 1005 
MAb C-1 IgG1 κ IGHV1 IGKV1 CH2 253 591 
MAb C-2 IgG2 κ IGHV1 IGKV1 CH2 139 303 
MAb C-4 IgG4 κ IGHV1 IGKV1 CH2 202 565 
MAb D-1 IgG1 κ IGHV1 IGKV3 VH,  CH2
f) 190 540 
MAb D-2 IgG2 κ IGHV1 IGKV3 VH,  CH2
f) 99 264 
MAb D-4 IgG4 κ IGHV1 IGKV3 VH,  CH2
f) 125 496 
MAb E IgG1 κ IGHV1 IGKV1 CH2 242 624 
MAb F IgG1 κ IGHV3 IGKV1 CH2 233 659 
MAb G IgG1 κ IGHV3 IGKV1 CH2 271 656 
MAb H IgG1 κ IGHV3 IGKV1 CH2 254 632 
MAb I IgG1 κ IGHV3 IGKV3 CH2 289 644 
MAb J IgG1 κ IGHV3 IGKV6 CH2 250 637 
MAb K IgG1 κ IGHV3 IGKV6 CH2 275 692 
MAb L IgG1 κ IGHV4 IGKV3 CH2 241 655 
MAb M IgG1 κ IGHV4 IGKV3 CH2 248 689 
MAb N IgG1 κ IGHV4 IGKV3 CH2 239 680 
MAb O IgG1 κ IGHV4 IGKV3 CH2 274 708 
MAb P IgG1 κ IGHV4 IGKV3 CH2 257 667 
MAb Q IgG1 κ IGHV4 IGKV3 CH2 262 638 
MAb R IgG1 κ IGHV4 IGKV1 CH2 210 658 
MAb S IgG1 κ IGHV5 IGKV1 CH2 249 665 
MAb T IgG1 λ IGHV1 IGLV1 CH2 203 517 
MAb U IgG1 λ IGHV3 IGLV7 CH2 223 524 
MAb V IgG1 λ IGHV7 IGLV3 CH2 176 394 
MAb W IgG1 λ IGHV3 IGLV1 CH2 242 487 
MAb 1 IgG4 κ IGHV3 IGKV3 CH2 211 655 
MAb 2 IgG4P
e) κ IGHV4 IGKV3 CH2 210 673 
MAb 3 IgG4PE
d) κ IGHV3 IGKV1 CH2 188 1014 
MAb 4 IgG4PE
d) κ IGHV3 IGKV1 CH2 190 1011 
MAb 5 IgG4PE
d) κ IGHV4 IGKV1 CH2 229 877 
MAb 6 IgG4PE
d) κ IGHV4 IGKV3 CH2 201 963 
a) Germline family was determined according to the immunogenetics nomenclature rules [20, 21]. 
b) Peak Na+ concentration in hydroxyapatite chromatography by NaPi gradient elution [13]. 
c) Peak NaCl concentration in hydroxyapatite chromatography by NaCl gradient elution with 5 mM NaPi in the gradient buffers. 
d) Ser228Pro and Leu235Glu mutated forms of the IgG4 heavy chain [19]. 
e) Ser228Pro mutated form of the IgG4 heavy chain [18]. 
f) Presence of N-glycan in the VH region was confirmed by sugar-cha in analysis. 
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2.3.2. Instrumentation and materials for chromatography experiments 
Chromatography experiments were performed on an Alliance HPLC workstation 
(Waters, Milford, MA, USA). Ceramic hydroxyapatite type II with an average bead size 
diameter of 20 µm (BioRad Laboratories, Hercules, CA, USA) was used as the 
chromatography medium, and was packed into a glass column of 3 mm internal diameter 
and 50 mm height (Kyoshin Kogyo, Tokyo, Japan). Sodium phosphate dibasic 
dodecahydrate (Junsei Chemical Co. Ltd., Tokyo, Japan), sodium phosphate monobasic 
dihydrate (Kokusan Chemical Co. Ltd., Tokyo, Japan), sodium chloride (Tomita 
Pharmaceutical Co. Ltd., Tokushima, Japan), HEPES (Dojindo Laboratories, Kumamoto, 
Japan), sodium hydroxide (Kokusan Chemical Co. Ltd.) and purified water were used to 
prepare the chromatography buffers. All reagents used were of analytical or 
pharmaceutical grade. 
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2.3.3. Hydroxyapatite chromatography by the NaCl gradient elution 
method 
Both 5 mM NaPi, pH 6.8 (buffer A) and 2 M NaCl in 5 mM NaPi, pH 6.8 (buffer B) 
were used as the equilibration and elution buffers, respectively, for the NaCl gradient 
elution method with NaPi in the chromatography buffers. For the NaCl gradient elution 
method with HEPES in the chromatography buffers, 5 mM HEPES, pH 6.8 (buffer C) 
and 2 M NaCl in 5 mM HEPES, pH 6.8 (buffer D) were used. The flow rate was 0.35 
mL/min. Samples were loaded on the hydroxyapatite column at 0.035 mg rhMAb/mL 
hydroxyapatite. The sample injection volume was 50 µL. After washing the column with 
buffer A or buffer C for 5 min, elution was performed for 30 min with a linear gradient 
from buffer A to buffer B, or from buffer C to buffer D, followed by a 2-min step elution 
with buffer B or buffer D. The column was regenerated with 400 mM NaPi, pH 6.8 
(buffer E) at 0.7 mL/min for 13 min. Chromatographic runs were performed at 25°C, and 
the column effluent was monitored at 215 nm and 280 nm. The baseline absorbance at 
215 nm increased during gradient elution, and the correlation formula between run time 
and NaCl concentration of the column effluent could be calculated. The CNaCl value for 
each rhMAb was determined using the correlation formula and peak retention time. 
Chromatography experiments for each rhMAb sample were conducted in duplicate, and 
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the average CNaCl values were used for interpretation. 
 
2.3.4. Hydroxyapatite chromatography by the NaPi gradient elution 
method 
The hydroxyapatite column was equilibrated with 5 mM NaPi, pH 6.8 (buffer A). 
The flow rate was 0.35 mL/min. Samples were loaded onto the column at 0.035 mg 
rhMAb/mL hydroxyapatite. The sample injection volume was 50 µL. After washing the 
column with buffer A for 5 min, elution was performed for 30 min with a linear gradient, 
from buffer A to 400 mM NaPi, pH 6.8 (buffer E). The column was regenerated with 
buffer E for 2 min. Chromatographic runs were performed at 25°C, and the column 
effluent was monitored at 280 nm. 
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2.4. Results and Discussion 
2.4.1. Hydroxyapatite chromatography of 37 rhMAbs performed by 
NaCl gradient elution with NaPi in the chromatography buffers 
Chromatography experiments by NaCl gradient elution were performed using the 37 
rhMAbs in the presence of 5 mM NaPi in the binding and elution buffers to correlate the 
retention times of rhMAbs (CNaCl) with their structures. Classification of the rhMAbs is 
shown in Table 2.1, according to subclass, type of light chain, and germline family of the 
variable regions, and includes 19 κ IgG1, 4 λ IgG1, 4 κ IgG2, and 10 κ IgG4 antibodies. 
Table 2.1 also includes peak sodium ion concentration values in NaPi gradient 
hydroxyapatite chromatography obtained in our previous study [13]. According to the 
inserted point mutations in the hinge region and the second heavy chain constant region 
(CH2 region), 10 κ IgG4 rhMAbs can be further classified into three groups of antibodies: 
3 IgG4, 1 IgG4P, and 6 IgG4PE. MAbs D-1, D-2, and D-4 contain an N-glycan structure 
between the second and third complementarity determining regions. The 12 rhMAbs 
from MAb A-1 to MAb D-4 comprise four sets of variable domain-identical antibodies. 
Thus, the rhMAbs of each group have identical amino acid sequences in the variable 
regions, and only differ by subclass (IgG1, IgG2, or IgG4 or IgG4PE). Wide variation 
found in the germline family of both VH and VL regions in the selected rhMAbs ensures 
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the diversity required in the present study (Table 2.1). 
From a comparison of the CNaCl values of each rhMAb sample, an apparent 
relationship could be observed between the CNaCl value and the heavy chain subclass for 
the κ IgG rhMAbs, except for MAbs D-1, D-2, and D-4 (Fig. 2.1). The retention times 
were broadly classified into three groups as follows: (1) κ IgG2, (2) κ IgG1, κ IgG4 and κ 
IgG4P, and (3) κ IgG4PE. Additionally, the elution order of MAbs C-1 vs. C-4 and MAbs 
D-1 vs. D-4 showed that κ IgG4 rhMAb eluted slightly earlier than its κ IgG1 subclass 
isotype. Although the CNaCl value varied among the subclass-identical rhMAbs 
possessing the same type of light chain (e.g., κ IgG1 rhMAbs), this variation was not 
large compared with the variation among the subclass isotypes (e.g., MAbs A-1, A-2, and 
A-4). With respect to the contribution of light chain types, the λ IgG1 rhMAbs eluted 
earlier than the κ IgG1 counterparts. As shown in Fig. 2.1, IgG2 rhMAbs exhibited the 
earliest elution time compared with IgG1 and IgG4 rhMAbs, which is in agreement with 
the results of Wensel et al. [10]. Although they report that IgG1 and IgG4 humanized 
MAbs were indistinguishable in their binding to hydroxyapatite, we found that κ IgG4 
rhMAbs eluted slightly earlier than their κ IgG1 subclass isotypes. This is because we 
utilized the subclass isotypes with the same Fab region (MAbs C or MAbs D). With 
regard to the light chain types, the λ IgG1 rhMAbs tended to elute earlier than the κ IgG1 
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counterparts. Wensel et al concluded that there were no consistent trends in the binding 
between κ IgG and λ IgG MAbs [10]; however, their data indicated a similar tendency 
under the conditions of the present study (NaPi concentration: 5 mM, pH6.8). Obviously, 
the κ IgG4PE rhMAbs showed the latest retention times, despite the fact that the 
retention times of κ IgG4PE and κ IgG4 rhMAbs in NaPi gradient hydroxyapatite 
chromatography did not show any difference due to the mutation [13], and that the 
retention times in the NaPi gradient chromatography showed a common positive 
linearity with the number of surface distributed basic amino acid residues [13]. MAbs 
D-1, D-2, and D-4, which have N-glycan structures in their VH regions, eluted the 
earliest among their subclass-identical κ IgG rhMAbs, probably due to interference by 
binding to hydroxyapatite. The same tendency was observed in the retention behavior in 
NaPi gradient chromatography [13], which showed that these rhMAbs did not meet the 
linear trend between retention times and basic residues of rhMAbs without N-glycan in 
the VH regions. 
From these results, the retention behavior of rhMAbs in the NaCl gradient 
hydroxyapatite chromatography with 5 mM NaPi in the chromatography buffers could 
be classified according to subclass and type of light chain.
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Fig. 2.1. Peak NaCl concentration values of rhMAbs in hydroxyapatite chromatography obtained by NaCl gradient elution with 5 mM NaPi in the 
chromatography buffers. Column: Ceramic hydroxyapatite type II, 20-µm beads, 3-mm diameter × 50-mm length; binding buffer: 5 mM NaPi, pH 
6.8; elution buffer: 2 M NaCl in 5 mM NaPi, pH 6.8; elution: 30 min, with a linear gradient from the binding buffer to the elution buffer at a flow 
rate of 0.35 mL/min; injection: 0.035 mg rhMAb/mL hydroxyapatite. 
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2.4.2. NaCl gradient elution without NaPi in the chromatography 
buffers 
Chromatography experiments by NaCl gradient elution methods without NaPi in the 
gradient buffers were performed for the 20 rhMAbs (MAbs A-1 to D-4, T to W, 1, 2, 5, 
and 6) to further clarify the retention behavior of rhMAbs. The method was the same as 
that used for the experiments in section 2.4.1 except for the gradient buffers: 5 mM 
HEPES, pH 6.8, was used for the binding buffer, and 2 M NaCl in 5 mM HEPES, pH 6.8 
for the elution buffer. The CNaCl values obtained are compared in Fig. 2.2. 
The results show that only the κ IgG2 and κ IgG4 rhMAbs were eluted by the NaCl 
gradient elution without NaPi. On the other hand, κ IgG1, κ IgG4PE, and λ IgG1 rhMAbs 
were not eluted even with 2 M NaCl, and were finally eluted in the regeneration step 
with 400 mM NaPi, pH 6.8. Although the CNaCl values of κ IgG1 and κ IgG4 rhMAbs 
were similar (but to be exact, κ IgG4 < κ IgG1) in NaCl gradient hydroxyapatite 
chromatography with 5 mM NaPi in the gradient buffers, only the κ IgG4 rhMAbs were 
eluted by the NaCl gradient elution without NaPi. The CNaCl values of all subclasses 
apparently increased by removing the low concentration NaPi from the chromatography 
buffers, indicating that metal-affinity interactions are involved in the adsorption for all 
subclasses. Although metal-affinity interactions were not thought to be affected by 
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conductivity, Gagnon et al. suggested that weak metal-affinity interactions could be 
broken by increasing conductivity [22]. Thus, it can be considered that the metal-affinity 
interactions of IgG2 and IgG4 rhMAbs are relatively weak compared with those of IgG1 
and IgG4PE rhMAbs. 
The elution of κ IgG4 rhMAbs but not λ IgG1 rhMAbs by NaCl in the absence of 5 
mM NaPi suggests stronger metal-affinity interactions of λ IgG1 rhMAbs than κ IgG4 
rhMAbs; however, the λ IgG1 rhMAbs tended to elute earlier than the κ IgG4 rhMAbs by 
NaCl gradient elution with NaPi (Figs. 2.1 and 2.2). These results suggest that some 
other interaction mechanisms would contribute to the retention behavior in the NaCl 
gradient elution mode with 5 mM NaPi. 
Together with the results described in sections 2.4.1 and 2.4.2, it is suggested that 
each heavy chain subclass or light chain subclass can be separated by hydroxyapatite 
chromatography when an appropriate buffer composition is selected. 
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Fig 2.2. Plot of the retention times of 20 rhMAbs (MAbs A-1 to D-4, T to W, 1, 2, 5, and 6) in 
hydroxyapatite chromatography obtained by NaCl gradient elution with and without NaPi in the 
gradient buffers. Column: Ceramic hydroxyapatite type II, 20-µm, 3-mm diameter × 50-mm 
length; binding buffer (black diamond): 5 mM NaPi, pH 6.8, (white circle): 5 mM HEPES, pH 
6.8; elution buffer (black diamond): 2 M NaCl in 5 mM NaPi, pH 6.8, (white circle): 2 M NaCl 
in 5 mM HEPES, pH 6.8; elution: a 30 min linear gradient from the binding buffer to the elution 
buffer at a flow rate of 0.35 mL/min; Regeneration: 400 mM NaPi, pH 6.8 at 0.7 mL/min for 13 
min; injection: 0.035 mg rhMAb/mL hydroxyapatite. The κ IgG1, κ IgG4PE, and λ IgG1 rhMAbs 
were not eluted even with 2 M NaCl, and were finally eluted in the regeneration step with 400 
mM NaPi. 
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2.4.3. Interaction of the glutamate residue in IgG4PE with 
hydroxyapatite 
IgG4PE rhMAb has two point mutations: Ser228Pro in the hinge region and 
Leu235Glu in the CH2 region. The CNaCl values of the IgG4PE rhMAbs in the presence of 
5 mM NaPi are clearly higher than the CNaCl values of the IgG4 and IgG4P rhMAbs (Fig. 
2.1). To investigate the effects of Glu-235 on the retention behavior, we compared the 
chromatograms of κ IgG4P and κ IgG4PE rhMAbs by NaPi gradient elution and by NaCl 
gradient elution with 5 mM NaPi (Figs. 2.3A and 2.3B). The amino acid sequences of the 
two rhMAbs only differ at the residue at position 235 in the heavy chain. These two 
rhMAbs eluted at exactly the same retention time in the NaPi gradient elution (Fig. 
2.3A); however, IgG4PE rhMAb eluted apparently later than the IgG4P rhMAb in the 
NaCl gradient elution (Fig. 2.3B). Since the coordination of closely located carboxyl 
groups on glutamate or aspartate residues are reported to generate metal-affinity 
interactions [6–9], it was suggested that the Glu-235 residues of IgG4PE antibodies were 
involved in forming strong metal-affinity interactions and contributed to the retention 
behavior. The Glu-235 residues, which are located in the CH2 regions, are adjacent to the 
disulfide bridge in the hinge region. Although there is limited 3D structural information 
on this region of human IgG4 proteins, two negatively charged amino acid residues are 
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believed to be located close to the Glu-235 residue: a Glu residue at position 233 and 
another Glu residue at position 235 on the paired CH2 region. The coordination of these 
Glu residues is expected to generate one or two metal-affinity interactions between 
IgG4PE rhMAb and hydroxyapatite. 
The peak retention times of the IgG4PE and the IgG4P rhMAb were completely 
identical by NaPi gradient elution (Fig. 2.3A). Additionally, in our previous study 
regarding NaPi gradient elution, the retention times of the κ IgG4PE and κ IgG4 rhMAbs 
showed a common positive linearity with the number of surface distributed basic amino 
acid residues [13]. These results indicate that the generated metal affinity interactions by 
Glu-235 do not influence the retention behavior in the NaPi gradient elution. 
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Fig 2.3. Hydroxyapatite chromatograms of a κ IgG4P rhMAb and its Leu235Glu mutated form (κ 
IgG4PE rhMAb) obtained by (A) NaPi gradient elution, and (B) NaCl gradient elution with 5 
mM NaPi in the gradient buffers. Column: Ceramic hydroxyapatite type II, 20-µm, 3-mm 
diameter × 50-mm length; binding buffer: 5 mM NaPi, pH 6.8; elution buffer (A): 2 M NaCl in 5 
mM NaPi, pH 6.8, (B): 400 mM NaPi, pH 6.8; elution: a 30 min linear gradient from the binding 
buffer to the elution buffer at a flow rate of 0.35 mL/min; injection: 0.035 mg rhMAb/mL 
hydroxyapatite. The small trailing peak or shoulder appearing after the main peak is considered 
an antibody aggregate [4, 5, 22]. 
 
 
2.4.4. Comparison of retention times of NaCl elution with those of NaPi 
elution 
Figure 2.4 shows the plots of the peak NaCl concentration against the peak NaPi 
concentration for all 37 rhMAbs. The retention time values by NaPi gradient elution 
(Table 2.1) were obtained in our previous study [13]. Positive correlation was observed 
between the retention times by these two gradient modes except for IgG4PE rhMAbs, 
which showed apparently higher retention time values by NaCl gradient elution 
compared with other subclasses. 
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The results in section 2.4.3 indicated that the replaced amino acid residue of Glu-235 
in κ IgG4PE rhMAbs does not greatly affect the retention time in NaPi gradient elution, 
although the generated metal affinity interactions on the κ IgG4PE rhMAbs by the 
alteration of Leu235Glu are supposed to be the strongest. Thus, it is suggested that the 
major separation mode of the NaPi gradient hydroxyapatite chromatography is 
cation-exchange, although both phosphoryl cation exchange interactions and 
metal-affinity interactions contribute to the binding of rhMAbs to hydroxyapatite. 
In the NaCl gradient hydroxyapatite chromatography with 5 mM NaPi, the 
phosphoryl cation exchange interactions may affect the retention times of rhMAbs 
because the retention times of these rhMAbs by NaCl and NaPi gradient elutions showed 
a positive correlation (Fig. 2.4). However, the retention times of IgG4PE rhMAbs were 
markedly higher than those of other subclasses. Furthermore, the correlation between 
retention time and the number of surface-distributed basic amino acid residues observed 
in the elution with NaPi gradient [13], was not observed in the present elution with the 
NaCl gradient with 5mM NaPi (data not shown). From these observations, interaction 
mechanisms other than the phosphoryl cation exchange interactions—most probably 
metal affinity interactions—must affect the retention behavior cooperatively. Compared 
to the NaPi gradient elution, the contribution of the metal affinity interaction is greater in 
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the NaCl gradient elution. This interpretation is in good agreement with previous 
publications that consider the cooperation of both interaction mechanisms for whole 
antibody molecules [22], and that found that calcium-metal-affinity interactions of 
antibodies are affected by increasing conductivity [11, 22]. In IgG4PE rhMAbs, the metal 
affinity interaction is supposed to be dominant because these rhMAbs apparently did not 
meet the linear trends indicated in Fig. 2.4. 
Regarding κ IgG and λ IgG rhMAbs, the λ IgG1 rhMAbs eluted earlier than κ IgG1 
rhMAbs (Fig. 2.1). λ IgG has been known to have conformational flexibility between the 
variable and constant domains. Such a structural difference may influence accessibility 
of the antibodies to hydroxyapatite. 
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Fig 2.4. Comparison of retention times by NaPi gradient elution and NaCl gradient elution with 5 
mM NaPi. The values obtained are presented in Table 1. Column: Ceramic hydroxyapatite type II, 
20-µm, 3-mm diameter × 50-mm length; binding buffer: 5 mM NaPi, pH 6.8; elution buffer 
(NaPi gradient): 400 mM NaPi, pH 6.8, (NaCl gradient): 2 M NaCl in 5 mM NaPi, pH 6.8; 
elution: a 30 min linear gradient from the binding buffer to the elution buffer at a flow rate of 
0.35 mL/min; injection: 0.035 mg rhMAb/mL hydroxyapatite. The correlation coefficient was 
calculated using the data, except that for the κ IgG4PE rhMAbs. 
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2.5. Concluding remarks 
In the hydroxyapatite chromatography of rhMAbs by NaCl gradient elution in the 
presence of 5 mM NaPi, it was suggested that the retention time could be classified by 
subclass and type of light chain. In the absence of NaPi in the chromatography buffer, 
IgG1 and IgG4 rhMAbs were not eluted even with 2M NaCl. Retention time is supposed 
to be affected by phosphoryl cation exchange interactions under a buffer composition 
with 5 mM NaPi in the gradient buffer. However, the separation mode is not the single 
ion exchange; other interaction mechanisms of metal affinity interaction would also be 
involved. That is, the cation exchange and metal affinity interactions affect the retention 
behavior cooperatively. The contribution of metal affinity interactions is greater in NaCl 
gradient hydroxyapatite chromatography than in NaPi gradient elution chromatography. 
Furthermore, for IgG4PE rhMAbs, metal-affinity interactions would be dominated in 
hydroxyapatite chromatography with NaCl gradient elution. 
Hydroxyapatite chromatography is a powerful method for purifying MAbs. 
Understanding the retention behavior of the antibodies required is useful for the design 
of MAb purification methods. Thus, the different elution propensities of MAbs that 
depend on the MAb structures (heavy chain subclasses, light chain isotypes, and the 
number of surface distributed basic amino acid residues) and gradient elution buffers 
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(NaPi or NaCl), as discovered in our previous [13] and present studies should be 
informative for the efficient purification-process development of rhMAbs.
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CONCLUSIONS 
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Hydroxyapatite chromatography is one of the efficient chromatography tools for 
rhMAbs production. In this study, retention behavior of various rhMAbs in 
hydroxyapatite chromatography by each of NaPi and NaCl gradient elution methods 
was investigated according to the physicochemical properties of the antibody structures. 
The following features are the principal results obtained in the present study: 
 
1. NaPi gradient elution: 
(i) The structure of both constant and variable regions affects the retention time 
independently. 
(ii)  The number of positively charged amino acid residues in the variable region, 
particularly in the heavy chain, correlates well with the retention behavior. 
(iii) Among rhMAbs of same constant regions (subclass, type of light chains), the 
correlation is more pronounced when the surface accessibility of the     
positively charged amino acid residues are taken into consideration. 
(iv) λ IgG rhMAbs tend to elute earlier than κ IgG rhMAbs when their subclass is 
identical. 
(v)  N-glycan structures on the VH regions might inhibit the interaction. 
(vi) The major separation mode is cation-exchange, although both phosphoryl cation     
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exchange interactions and metal-affinity interactions contribute to the     
binding of rhMAbs to hydroxyapatite. 
(vii)  Although pI value of protein is reported to show a positive correlation to the 
retention behavior in hydroxyapatite chromatography by NaPi elution, such a 
correlation for antibody was not observed in the present study. 
 
2. NaCl gradient elution: 
(i)  The retention time can be classified by subclass and type of light chain. 
(ii)  λ IgG rhMAbs tend to elute earlier than κ IgG rhMAbs of the same subclass. 
(iii)  N-glycan structures on the VH regions might inhibit the interaction. 
(iv) The cation exchange and metal affinity interactions affect the retention behavior 
cooperatively. 
(v) The contribution of metal affinity interactions is greater in the NaCl gradient elution 
chromatography than in NaPi gradient elution chromatography.  
 
From these results, it was found that the retention behavior of human antibodies in 
hydroxyapatite chromatography can be classified according to the primary structure of 
the antibodies. Reliable prediction of the retention time in column chromatography 
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purification according to readily obtained information, such as the amino acid sequence 
of target MAbs, can serve as a guide for the optimization of the elution buffer 
conditions as well as the estimation of purity levels, which will facilitate the 
development of purification processes. For example, by compiling preliminary 
information about the retention time of the impurities such as production cell-derived 
proteins, genomic DNA, and components of the cell culture media, the effect of removal 
of those impurities through the purification of the target MAbs can be predicted. 
Therefore, under the conditions of heated competition in a growing market of antibody 
therapy, these findings will help to minimize the development period in the early stage 
of process development. 
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